We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Biomarker Helps Predict Stomach Cancer Survival

By LabMedica International staff writers
Posted on 16 Sep 2015
A biomarker has been identified in patients with stomach cancer that starves tumors of their blood supply and reduces the ability of cancer cells to spread to other parts of the body. More...


In the USA, stomach cancer, also known as gastric cancer, most commonly affects older people, as around 60% of those diagnosed each year are over 65. Stomach cancer is most common in less developed countries, and it is a primary cause of cancer-related deaths worldwide.

Scientists at the Southern Medical University (Guangzhou, China) used a form of genetic analysis called quantitative real-time polymerase chain reaction (qRT-PCR) to detect micro ribonucleic acid 506 (miR-506) in human gastric samples taken from 84 people who had undergone cancer surgery. The team analyzed the miR-506 levels in each of these samples, and patients were allocated to different groups based on whether they were above or below the mean miR-506 level.

They found that miR-506 expression was a useful marker for stratifying patients from early to advanced clinical stages and for overall survival prediction. Overexpression of miR-506 inhibited the epithelial-to-mesenchymal transition of gastric cancer cells; however, depletion of miR-506 promoted it. In addition, miR-506 suppressed gastric cancer angiogenesis and was associated with decreased matrix metalloproteinase-9 expression. They also found that V-Ets Avian Erythroblastosis virus E26 Oncogene Homolog 1 (ETS1) was a miR-506 target, and it was expressed in 71.10% of gastric cancer tissue samples. At 60 months, cumulative survival was approximately 30% in the low-miR-506 expression group, compared with 80% in the high-expression group.

The team then looked at signs of miR-506 in seven stomach cancer cell lines. Here, it was found that stomach cancer cells had lower levels of miR-506 than normal stomach tissue. Analysis of cells grown in vitro then showed that miR-506 levels were lowest in the cell lines that had the highest invasive activity, and the highest levels were seen in cell lines with the lowest invasive activity.

Xin Song, MD, PhD, the lead investigator, said, “Our findings indicate that miR-506 is necessary and sufficient for angiogenesis suppression during gastric cancer progression. Cancer is a complex disease and controlling cancer development and progression requires system level and integrative approaches. Our study suggests that miR-506 acts as a tumor suppressor in gastric cancer." The study was published on September 8, 2015, in the American Journal of Pathology.

Related Links:

Southern Medical University 



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.